Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Current therapies for advanced HCC and their limitations

Michael Pishvaian • 16 Nov 2018
ESMO 2018
Gastrointestinal Cancer Liver Cancer Atezolizumab Bevacizumab Lenvatinib Nivolumab Regorafenib Sorafenib

The hepatocellular carcinoma (HCC) treatment landscape has expanded in all settings, with multi-kinase and immune checkpoint inhibitors taking center stage. At the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Michael Pishvaian, MD, PhD, of Georgetown University, Washington, WA, discusses the efficacy and limitations of emerging agents such as bevacizumab, regorafenib and lenvatinib, as well as their role in disease biology and combination regimens.

More from Michael Pishvaian

2:40
Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC
Michael Pishvaian • 16 Nov 2018
1:48
Upcoming IO combinations for advanced HCC
Michael Pishvaian • 16 Nov 2018

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals